You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Immunosuppressive agent; blocks phagocytosis, cytokine production and proliferation of T and B cells. Non-competitively inhibits chymotrypsin-like activity of 20S proteasome; prevents degradation of IκBα, an endogenous blocker of NF-κB. Inhibits leukotriene B4 (LTB4) biosynthesis via inhibition of LTA4 hydrolase. Also inhibits farnesyltransferase and geranylgeranyltransferase I (IC50 values are 80 and 17 μM respectively) and displays antitumor activity against breast cancer in vivo.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble in DMSO and in ethanol|
References are publications that support the biological activity of the product.
Waring and Beaver (1996) Gliotoxin and related epipolythiodioxopiperazines. Gen.Pharmacol. 27 1311 PMID: 9304400
Fitzpatrick et al (2000) In vitro and in vivo effects of gliotoxin, a fungal metabolite: efficacy against dextran sodium sulfate-induced colitis in rats. Dig.Dis.Sci. 45 2327 PMID: 11258552
Vigushin et al (2004) Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumour activity against breast cancer in vivo. Med.Oncol. 21 21 PMID: 15034210
König et al (2019) Gliotoxin from Aspergillus fumigatus abrogates leukotriene B4 formation through inhibition of leukotriene A4 hydrolase. Cell Chem.Biol. 26 524 PMID: 30745237
If you know of a relevant reference for Gliotoxin, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Gliotoxin, Gliotoxin supplier, inhibitors, 20S, proteasome, immunosuppressant, inhibits, NF-κB, NF-kappaB, NF-kB, cytokine, production, Farnesyltransferase, geranylgeranyltransferase, I, Proteinases, Proteases, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Post-translational, Modification, Aspergillin, Protein, Prenyltransferases, NF-kB/IkB, Proteasome, Modifications, Immunosuppressants, LTA4, Hydrolase, 2637, Tocris Bioscience
1 Citation for Gliotoxin
Citations are publications that use Tocris products. Selected citations for Gliotoxin include:
Park et al (2019) Gliotoxin Enhances Autophagic Cell Death via the DAPK1-TAp63 Signaling Pathway in PTX-Resistant Ovarian Cancer Cells. Mar Drugs 17 PMID: 31336860
Do you know of a great paper that uses Gliotoxin from Tocris? Please let us know.
Reviews for Gliotoxin
There are currently no reviews for this product. Be the first to review Gliotoxin and earn rewards!
Have you used Gliotoxin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Targeted Protein Degradation Research Product Guide
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
- Active Degraders
- Degrader Building Blocks
- Custom Degrader Services
- UPS Proteins and Assays
- Assays for Protein Degradation
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia